| News

DayOne Accelerator finalizes participants

20.11.2019

BaselArea.swiss manages the DayOne initiative, which is now organizing the second round of the DayOne Accelerator. The participants are Digital Health startups promoting the health of children and young people.

DayOne Conference 2019

The DayOne Accelerator has chosen six participants, of whom four will receive non-dilutive funding of 50,000 Swiss francs, announced a statement. All the participants will benefit from BaselArea.swiss, which is providing support by connecting them to a network of potential partners and customers, including the particularly distinguished University Children’s Hospital Basel (UKBB).

A total of 120 startups applied to the competition, and 14 were shortlisted. These companies worked in part with UKBB to develop their business ideas, before six were chosen by a panel of experts from the region to progress to the accelerator. One of the participants is the Basel company Nutrix, which is developing a nanosensor for glucose monitoring in saliva to prevent diabetes. Virtual Doctors is another – a telemedicine company that supports healthcare professionals who provide care in Zambia.

The four companies that will receive a place on the program and financial support include the Basel company Zoundream , whose goal is to help identify the messages and potential pathologies in babies’ crying. Another is Haako, also Basel-headquartered, which is helping parents of children with asthma to better manage their condition. Rekonas (e Tomo), a spinoff from the University of Basel, is working on improved bedside monitoring of epilepsy. Finally, Wello Health is a Romanian company that helps families with overweight children to improve nutrition.

During the six-month program, the participants will learn from the accelerator – but the organizers will in turn learn from the startups’ developments, according to Fabian Streiff, Director Healthcare Innovation – DayOne at BaselArea.swiss. He said: “We understand that the process of taking a venture from a good idea to a viable venture in digital health is challenging and that these entrepreneurs need support.”

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Novartis Campus
Basel Area Business & Innovation, Switzerland Innovation Park

Switzerland Innovation Park Basel Area Site Novartis Campus

We are happy to present our latest addition to the Switzerland Innovation Park Basel Area: Our site on the Novartis Campus dedicated to digital health provides a focal point to a unique community of digital healthcare experts.

Read More
Basel Area Business & Innovation, Switzerland Innovation Park

The innovation and enterprise campus GRID is filling up

Two institutes from the University of Basel and a pharmaceutical company are relocating to the GRID innovation and enterprise campus, which is currently under construction at BaseLink in Allschwil. The new building will also contain the headquarters of the Switzerland Innovation Park Basel Area in future.

Read More
Basel Area Business & Innovation, Innovation

Artidis ends successful study

Artidis, a startup from Basel, has developed a nanotechnology platform that can be used for cancer diagnosis, among other things. The platform has now been tested in a study that was able to achieve its primary endpoint.

Read More
Basel Area Business & Innovation, Innovation

Startup Academy celebrates anniversary

Startup Academy is on the road to success ten years after being founded. The initiative has supported 280 startups to date. The project was originally started in Basel and is now represented at several locations in Switzerland with plans for further growth.

Read More
Basel Area Business & Innovation, Invest

Syngenta grows strongly and stays true to Basel

Syngenta AG, Adama and Sinochem are to be united under the umbrella of the new Syngenta Group. The group is headquartered in Basel and employs around 48,000 staff across over 100 countries.

Read More
Basel Area Business & Innovation, Innovation

Tolremo raises additional funding

The Muttenz-based biotechnology company Tolremo Therapeutics has raised an additional 4.7 million Swiss francs as part of a financing round. The company develops cancer therapies for precision medicine and is now driving forward clinical development.

Read More
Ruben Herrendorff, CEO Polyneuron Pharmaceuticals
Basel Area Business & Innovation, Innovation

Polyneuron medication receives orphan drug status in the USA

The American health authority has granted Polyneuron’s drug PN-1007 orphan designation. This status uses special conditions to balance out commercial disadvantages when developing drugs for rare diseases.

Read More
Basel Area Business & Innovation, Innovation

BaseLaunch Applications open

BaseLaunch helps build therapeutic ventures to the point where they can raise a Series-A financing round or similar.

Read More
Basel Area Business & Innovation, Innovation

i4Challenge Applications open

The i4Challenge is an acceleration program for SME, startups and new projects focused on innovative solutions, new approaches and next-generation products or services for Industry 4.0.

Read More
Basel Area Business & Innovation, Invest

Ricola earns the trust of Switzerland

Ricola has been voted the most trustworthy brand in Switzerland. The manufacturer of herbal candy, which is based in the Basel Area, previously won this award in 2017.

Read More
1 2 3 19

Do you have a question? We'd like to hear from you.